Siglec-3

Siglec-3

Siglec-3 詳細

Molecule Name
Myeloid cell surface antigen CD33
分子の別称
CD33,SIGLEC3,gp67
Drug Development Progress
治験薬の数44
市販薬剤の数1
研究&開発段階Approved
ターゲットの別称
Myeloid Cell Surface Antigen CD33,CD33 Molecule Transcript,CD33 Antigen,Siglec-3,P67,FLJ00391,Sialic acid-binding Ig-like lectin 3,CD33,CD33 Molecule,CD33 Antigen (Gp67),SIGLEC3,Gp67,Sialic Acid Binding Ig-Like Lectin 3
バックグランド
Myeloid cell surface antigen CD33 is also known as SIGLEC3, Siglecs (sialic acid binding Ig­like lectins) and GP67, is a single-pass type I membrane protein which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. Human CD33 / Siglec-3 cDNA encodes a 364 amino acid (aa) polypeptide with a hydrophobic signal peptide, an N-­terminal Ig-­like V­-type domain, one Ig­-like C2-­type domains, a transmembrane region and a cytoplasmic tail. CD33 / Siglec-3 usually considered myeloid-specific, but it can also be found on some lymphoid cells. In the immune response, CD33 / Siglec-3 may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. CD33 / Siglec-3 induces apoptosis in acute myeloid leukemia.

Siglec-3 製品リスト

Species
  • Human(14)
  • Cynomolgus(1)
  • Mouse(1)
  • Rat(1)
Tag
  • His Tag(9)
  • Fc Tag(4)
  • His Tag & Avi Tag(2)
  • Fc Tag & Avi Tag(1)
  • Llama IgG Fc Tag(1)
Host
  • HEK293(17)
Conjugate
  • Unconjugated(8)
  • Biotin-labeled(3)
  • FITC Labeled(2)
  • PE Labeled(2)
  • AF647 Labeled(1)
  • APC Labeled(1)
Grade
  • RUO(17)
Low Endotoxin
  • Yes(1)
  • No(16)
You Have Viewed 1-10 Of 17 Results
  • 1
  • 2

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
BL-M11D1BL-M11D1Phase 3 ClinicalBaili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd
Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
詳細
BI-836858BI-836858Phase 2 ClinicalC.H. Boehringer Sohn Ag & Co. Kg
Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
詳細
CART-33 (Chinese PLA General Hospital)Phase 2 ClinicalPla General Hospital
Leukemia, Myeloid; Leukemia, Myeloid, Acute
詳細
Lintuzumab Ac-225AC225-MOAB-M195; HuM195-Ac-225; 225Ac-HuM-195Phase 2 ClinicalPdl Biopharma Inc
Glioblastoma; Glioma; Gliosarcoma; Leukemia, Myeloid, Acute; Multiple Myeloma
詳細
CLL1/CD33/CD38/CD7 CAR-T cell therapyPhase 2 ClinicalGuangzhou Bio-Gene Technology Co Ltd
Leukemia, Myeloid, Acute
詳細
Universal donor derived CD33 CAR-NK cell therapy (Nationwide Children'S Hospital)Phase 2 ClinicalNationwide Children'S Hospital
Leukemia, Myeloid, Acute
詳細
CD33-CD123-CLL1 CART-T cell therapy (Hebei Taihe Chunyu Biotechnology)Phase 2 ClinicalHebei Tahoe Chunyu Biotechnology Co Ltd
Leukemia, Myeloid
詳細
VBP-301VBP301; VBP-301Phase 2 ClinicalVor Biopharma Inc
Leukemia, Myeloid, Acute
詳細
VBP-101VBP101; VBP-101Phase 2 ClinicalVor Biopharma Inc
Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
詳細
CAR-T Cells Targeting CD33/CD123 therapy(Essen Biotech)BAH244; BAH-244Phase 2 ClinicalEssen Biotech
Leukemia, Myeloid, Acute
詳細
MP0533MP0533Phase 2 ClinicalMolecular Partners Ag
Leukemia, Myeloid, Acute
詳細
CD33 CAR T Cells(Beijing Boren Hospital)Phase 2 ClinicalBeijing Gao Boren Hospital Co Ltd
Leukemia; Leukemia, Myeloid, Acute; Neoplasms
詳細
EmerfetamabAMG-673; AMG673Phase 1 ClinicalAmgen Inc
Leukemia, Myeloid, Acute
詳細
ICG-136ICG-136; 123b-33bcCARPhase 1 ClinicalIcell Gene Therapeutics (Int'L) Ltd
Leukemia, Myeloid, Acute
詳細
AL-003AL-003Phase 1 ClinicalAbbvie Inc, Alector Inc
Alzheimer Disease
詳細
PRGN-3006PRGN-3006; PRGN-3006 UltraCAR-TPhase 1 ClinicalPrecigen Inc
Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
詳細
anti-CD33 (FL-33) CAR T-cell therapy (Beijing GoBroad Hospital)Phase 1 ClinicalBeijing Gao Boren Hospital Co Ltd
Leukemia, Myeloid, Acute
詳細
anti-CD33/anti-CLL-1 CAR T-cell therapy (Nanjing Legend Biotech)Phase 1 Clinical
Leukemia, Myeloid, Acute
詳細
ORM-6151ORM-6151; BMS-986497Phase 1 ClinicalOrum Therapeutics Inc
Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
詳細
SENTI-202SENTI-202Phase 1 ClinicalSenti Biosciences Inc
Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
詳細
CD33Bi FPBMC (University Of Virginia)Phase 1 ClinicalUniversity Of Virginia
Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases
詳細
A-CAR028A-CAR028Phase 1 ClinicalCellular Biomedicine (Shanghai) Co Ltd
Leukemia, Myeloid, Acute
詳細
ACLX-004ACLX-004Phase 1 ClinicalArcellx Inc
Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
詳細
JNJ-89853413JNJ-89853413Phase 1 ClinicalJanssen Research & Development Llc
Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
詳細
GTB-3650GTB-3650; GTB-360; OXS-3350; OXS-C3550Phase 1 ClinicalMasonic Cancer Center, University Of Minnesota
Bone Marrow Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
詳細
RJK-RT2831RJK-RT2831; RJKRT2831; RT-2831; RT2831Phase 1 ClinicalNanjing RegeneCore Biotech Co Ltd
Hematologic Neoplasms
詳細
JNJ-67571244JNJ-1244; JNJ-67571244; JNJ-67371244Phase 1 ClinicalJohnson & Johnson
Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
詳細
CD33-NKECD33-NKEPhase 1 ClinicalBristol-Myers Squibb Company
Leukemia, Myeloid, Acute
詳細
Optimised CD33 (FL-33) CAR T Therapy(Beijing GoBroad Hospital)Phase 1 ClinicalBeijing GoBroad Hospital
Leukemia, Myeloid, Acute
詳細
Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute)Phase 1 ClinicalShenzhen Geno-Immune Medical Institute
Leukemia, Myeloid, Acute
詳細
CD33/CLL1 dual CAR-NK cell therapy (Hangzhou Qihan)Phase 1 ClinicalHangzhou Qihan Biotechnology Co Ltd
Leukemia, Myeloid, Acute; Neoplasm, Residual
詳細
CD33 CAR-NK cell therapy (Hangzhou Qihan)Phase 1 ClinicalHangzhou Qihan Biotechnology Co Ltd
Leukemia, Myeloid, Acute; Neoplasm, Residual
詳細
EluvixtamabAMG-330; MT-114Phase 1 ClinicalAmgen Inc
Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
詳細
IBR-733IBR-733; IBR733Phase 1 ClinicalImbioray (Hangzhou) Biomedicine Co Ltd
Leukemia, Myeloid, Acute
詳細
Anti-CD33 chimeric antigen receptor T cell therapy (Shanghai YaKe/Zhejiang University)Phase 1 ClinicalShanghai YaKe Biotechnology Co Ltd
Leukemia, Myeloid, Acute
詳細
CLL1+CD33 CAR-T(Zhejiang University)Phase 1 ClinicalZhejiang University
Leukemia, Myeloid, Acute
詳細
anti-CD33 CAR T cells therapy(iCell Gene Therapeutics)Phase 1 ClinicalIcell Gene Therapeutics (Int'L) Ltd
Hematologic Neoplasms; Leukemia, Myeloid, Acute
詳細
Lintuzumab Ac-225/VenetoclaxPhase 1 ClinicalActinium Pharmaceuticals Inc
Leukemia, Promyelocytic, Acute
詳細
SC-DARIC33SC-DARIC33; DARIC-33Phase 1 ClinicalGenetix Biotherapeutics Inc
Leukemia, Myeloid, Acute
詳細
DXC-007DXC-007Phase 1 ClinicalHangzhou Dac Biotech Company Ltd
Leukemia; Leukemia, Myeloid, Acute
詳細
Lintuzumab-gelonin conjugatePhase 1 ClinicalThe University Of Texas MD Anderson Cancer Center
Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
詳細
Anti-CD33/CLL-1 CAR-T (Legend)Phase 1 ClinicalLegend Biotech Corp
Leukemia, Promyelocytic, Acute
詳細
Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD)Phase 1 ClinicalUniversity Of California San Diego
Leukemia, Myeloid, Acute
詳細
Anti-CD33 CAR T cell therapy (Wuhan Bio-Raid)ClinicalWuhan BioRaid Biotechnology Co Ltd
Leukemia, Myeloid, Acute
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
Gemtuzumab ozogamicinCMA-676; CDP-771; WAY-CMA-676; CL-555201; hP67.6-calicheamicinApprovedPfizer Inc, Ucb SaMylotargJapanLeukemia, Myeloid, AcutePfizer Inc2008-01-18
Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Juvenile; Myelodysplastic Syndromes
詳細
Customer Reviews
  • K***n2023-05-06
    While transducing primary cells, I was running into a staining issue with biotinylated-rCD33. A colleague of mine had used rCD33 labelled with PE before and had success with a similar experiment. I decided to order from Acrobio Systems due to the recommendations and high praise from several colleagues. Upon staining, I saw great fluorescence, increased events caught, and higher transduction efficiencies. I will definitely be using this product again!
  • E***g2023-01-18
    We purchased this reagent for use in detecting CD33 CAR expression and it worked as advertised. The PE signal gave great separation by flow cytometry and allowed for the clear detection of CAR expression on the surface of our cells. The product page states that the CD33 PE reagent is incompatible with streptavidin-biotin detection systems. When we tried to co-stain with another biotinylated reagent, subsequent application of streptavidin-APC resulted in high non-specific APC staining. This could be avoided by staining with CD33 PE after all other staining steps have been completed.
  • S***s2023-01-12
    We purchased this antibody to use for flow cytometry on a client study, who specifically requested Acro antibodies! They are reliable and have continued to be one of our top providers of antibodies. We typically use multiple fluorescent antibodies with various protein targets and fluorophores at once for flow cytometry panels in human and mouse tissues, and Acro antibodies have always given us a great readout.